This is the authors' abstract. We don't add key points for this paper.
New drug modalities (NDMs) continue to redefine the pharmaceutical landscape by addressing "undruggable" targets and providing innovative therapeutics for various diseases. This third annual review summarizes 15 selected publications from 2025 that advance our understanding of NDM metabolism. We focus on four major categories: (1) PROTACs and molecular glues, with an emphasis on biotransformation and chiral stability; (2) Oligonucleotide therapeutics, including in vitro and in vivo metabolism of oligonucleotides as well as a workflow for metabolite identification; (3) Macrocyclic peptides, highlighting throughput enhancements and leader-independent cyclization; and (4) Conjugated drugs, encompassing antibody-drug conjugates (ADCs) and novel Fc-fusion proteins. This collection provides critical insights into metabolism, tissue distribution, and analytical innovations intended to accelerate the transition of these complex modalities from discovery to clinical application.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: